002821 凯莱英
已收盘 04-16 15:00:00
资讯
新帖
简况
凯莱英新提交“未公开”等2件商标注册申请
证券之星 · 04-15 06:40
凯莱英新提交“未公开”等2件商标注册申请
凯莱英获小摩增持9.56万股 每股作价约97.68港元
新浪港股 · 04-14 07:45
凯莱英获小摩增持9.56万股 每股作价约97.68港元
Norges Bank减持凯莱英(06821)26.32万股 每股作价约104.64港元
智通财经网 · 04-08
Norges Bank减持凯莱英(06821)26.32万股 每股作价约104.64港元
毛利率创上市来新低，凯莱英小分子业务仍处于调整阶段，多肽业务产能正爬坡
深圳商报·读创 · 04-07
毛利率创上市来新低，凯莱英小分子业务仍处于调整阶段，多肽业务产能正爬坡
凯莱英：展望2026年营业收入增长预计19%-22%
南方财经网 · 04-04
凯莱英：展望2026年营业收入增长预计19%-22%
凯莱英（002821）披露股票交易异常波动公告，4月3日股价下跌3.62%
证券之星 · 04-03
凯莱英（002821）披露股票交易异常波动公告，4月3日股价下跌3.62%
凯莱英最新公告：股票交易异常波动
证券之星 · 04-01
凯莱英最新公告：股票交易异常波动
4月1日凯莱英（002821）龙虎榜数据：机构净买入5723.67万元，北向资金净买入1576.32万元
证券之星 · 04-01
4月1日凯莱英（002821）龙虎榜数据：机构净买入5723.67万元，北向资金净买入1576.32万元
凯莱英：公司是一家全球行业领先的CDMO一站式综合解决方案提供商
证券之星 · 04-01
凯莱英：公司是一家全球行业领先的CDMO一站式综合解决方案提供商
凯莱英：公司近年推行的降本增效措施成果显著
证券之星 · 04-01
凯莱英：公司近年推行的降本增效措施成果显著
CXO概念股强势 凯莱英(06821)涨13.85% 机构认为CXO基本面拐点已经出现
金吾财讯 · 03-31
CXO概念股强势 凯莱英(06821)涨13.85% 机构认为CXO基本面拐点已经出现
凯莱英(06821)发布年度业绩 归母净利润约11.33亿元，同比增加19.35%
智通财经 · 03-30
凯莱英(06821)发布年度业绩 归母净利润约11.33亿元，同比增加19.35%
Schroders PLC增持凯莱英(06821)8.85万股 每股作价约79.03港元
智通财经 · 03-30
Schroders PLC增持凯莱英(06821)8.85万股 每股作价约79.03港元
凯莱英（002821）披露召开2026年第一次临时股东会等三会通知，3月25日股价上涨0.95%
证券之星 · 03-25
凯莱英（002821）披露召开2026年第一次临时股东会等三会通知，3月25日股价上涨0.95%
凯莱英（002821）披露董事会会议日期公告，3月16日股价下跌0.23%
证券之星 · 03-16
凯莱英（002821）披露董事会会议日期公告，3月16日股价下跌0.23%
凯莱英(06821)购回及注销部分根据2025年A股计划授予的限制性A股股份
智通财经 · 03-13
凯莱英(06821)购回及注销部分根据2025年A股计划授予的限制性A股股份
凯莱英：拟使用45.00亿闲置自有资金购买理财产品
南方财经网 · 03-13
凯莱英：拟使用45.00亿闲置自有资金购买理财产品
凯莱英（002821）披露证券变动月报表，3月3日股价下跌2.05%
证券之星 · 03-03
凯莱英（002821）披露证券变动月报表，3月3日股价下跌2.05%
花旗集团增持凯莱英H股，持股比例从9.34%升至11.67%
美股速递 · 02-25
花旗集团增持凯莱英H股，持股比例从9.34%升至11.67%
小摩增持凯莱英(06821)9400股 每股作价约87.56港元
智通财经 · 02-13
小摩增持凯莱英(06821)9400股 每股作价约87.56港元
公司概况
公司名称：
凯莱英医药集团(天津)股份有限公司
所属行业：
医药制造业
上市日期：
2016-11-18
主营业务：
凯莱英医药集团(天津)股份有限公司的主营业务是为国内外制药公司、生物技术公司提供药品全生命周期的一站式服务。公司的主要产品是小分子CDMO解决方案、新兴业务。凯莱英生物AsymBio偶联药物开发平台成功入围第12届WorldADCAwards“BestADCPlatformTechnology”奖项，印证了凯莱英生物在全球抗体偶联药物CDMO领域的卓越地位。
发行价格：
30.53
{"stockData":{"symbol":"002821","market":"SZ","secType":"STK","nameCN":"凯莱英","latestPrice":117.41,"timestamp":1776323034000,"preClose":117.85,"halted":0,"volume":8410005,"delay":0,"changeRate":-0.0037,"floatShares":317000000,"shares":361000000,"eps":3.6473,"marketStatus":"已收盘","change":-0.44,"latestTime":"04-16 15:00:00","open":117.24,"high":119.4,"low":115.5,"amount":988000000,"amplitude":0.0331,"askPrice":117.42,"askSize":10,"bidPrice":117.41,"bidSize":110,"shortable":0,"etf":0,"ttmEps":3.6473,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776389400000},"marketStatusCode":5,"adr":0,"adjPreClose":117.85,"symbolType":"stock","openAndCloseTimeList":[[1776303000000,1776310200000],[1776315600000,1776322800000]],"highLimit":129.64,"lowLimit":106.07,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":360874970,"isCdr":false,"pbRate":2.41,"roa":"--","peRate":32.190936,"roe":"6.58%","epsLYR":3.16,"committee":0.721116,"marketValue":42370000000,"turnoverRate":0.0265,"status":1,"hkstockBrief":{"symbol":"06821","market":"HK","secType":"STK","nameCN":"凯莱英","latestPrice":100.7,"timestamp":1776326892006,"preClose":98.65,"halted":0,"volume":300640,"delay":0,"premium":"-25.27"},"floatMarketCap":37224000000},"requestUrl":"/m/hq/s/002821/wiki","defaultTab":"wiki","newsList":[{"id":"2627427072","title":"凯莱英新提交“未公开”等2件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2627427072","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627427072?lang=zh_cn&edition=full","pubTime":"2026-04-15 06:40","pubTimestamp":1776206423,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示，近日凯莱英医药集团（天津）股份有限公司新提交“未公开”等2件商标注册申请。商标申请详情如下：今年以来凯莱英医药集团（天津）股份有限公司新申请注册商标2件，截止目前公司共持有注册商标49件，另有11件商标尚在注册申请中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500007124.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1191","BK0132","06821","002821","LU1328615791.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627649554","title":"凯莱英获小摩增持9.56万股 每股作价约97.68港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627649554","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627649554?lang=zh_cn&edition=full","pubTime":"2026-04-14 07:45","pubTimestamp":1776123900,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 香港联交所最新资料显示，4月8日，小摩增持凯莱英（06821）9.56万股，每股作价97.6752港元，总金额约为933.77万港元。增持后最新持股数目约为230.06万股，最新持股比例为8.26%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-04-14/doc-inhummyi9120601.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BJTD4V19.USD","LU0345769128.USD","LU0345770993.USD","LU0820561818.USD","LU1145028129.USD","JPMO","LU0496365809.HKD","IE00B775SV38.USD","LU0976567544.SGD","JPO","LU0211331839.USD","LU0689472784.USD","IE00BYXW3230.USD","IE00BJLML261.HKD","LU2023250504.SGD","LU0964807845.USD","LU0320765646.SGD","SG9999002232.USD","BK4534","BK4585","LU0971096721.USD","LU2237443622.USD","LU0211326839.USD","LU0265550359.USD","IE00BBT3K403.USD","LU1974910355.USD","LU0211328371.USD","LU1914381329.SGD","LU2456880835.USD","LU2505996681.GBP","LU0345769631.USD","IE00B1XK9C88.USD","LU0203347892.USD","BK4566","LU1629891620.HKD","LU0323591593.USD","LU1670627923.USD","IE00BHPRN162.USD","BK4516","LU1668664300.SGD","BK4550","LU2054465674.USD","LU1328615791.USD","002821","IE00BDCRKT87.USD","LU0006306889.USD","06821","LU0149725797.USD","LU1162221912.USD","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625945941","title":"Norges Bank减持凯莱英(06821)26.32万股 每股作价约104.64港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2625945941","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625945941?lang=zh_cn&edition=full","pubTime":"2026-04-08 18:59","pubTimestamp":1775645977,"startTime":"0","endTime":"0","summary":"香港联交所最新资料显示，4月2日，Norges Bank减持凯莱英(06821)26.32万股，每股作价104.6389港元，总金额约为2754.1万港元。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260408/20260408185955_73298.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260408/20260408185955_73298.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426104.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["002821","BK0239","BK1191","BK0132","EWH","LU1328615791.USD","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625640986","title":"毛利率创上市来新低，凯莱英小分子业务仍处于调整阶段，多肽业务产能正爬坡","url":"https://stock-news.laohu8.com/highlight/detail?id=2625640986","media":"深圳商报·读创","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625640986?lang=zh_cn&edition=full","pubTime":"2026-04-07 10:20","pubTimestamp":1775528416,"startTime":"0","endTime":"0","summary":"近日，凯莱英（002821）在业绩说明会上公司展望2026年时表示，营业收入增长预计19%~22%，就分业务板块而言，小分子业务目前仍处于调整阶段，商业化项目表现可圈可点，整体能够保持稳健态势。新兴业务有望持续保持高增长态势，两个大分子业务板块业绩预计将表现更为突出。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604073696240266.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1328615791.USD","002821","BK0132","BK1191","06821","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624151698","title":"凯莱英：展望2026年营业收入增长预计19%-22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624151698","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624151698?lang=zh_cn&edition=full","pubTime":"2026-04-04 09:02","pubTimestamp":1775264536,"startTime":"0","endTime":"0","summary":"南方财经4月4日电，凯莱英4月3日在业绩说明会表示，公司展望2026年营业收入增长预计19%-22%，分业务板块展望2026年：小分子业务目前仍处于调整阶段，商业化项目表现可圈可点，整体能够保持稳健态势。新兴业务有望持续保持高增长态势，两个大分子业务板块业绩预计将表现更为突出。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604043695524881.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06821","002821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624674656","title":"凯莱英（002821）披露股票交易异常波动公告，4月3日股价下跌3.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624674656","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624674656?lang=zh_cn&edition=full","pubTime":"2026-04-03 17:01","pubTimestamp":1775206892,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，凯莱英报收于122.06元，较前一交易日下跌3.62%，最新总市值为440.48亿元。该股当日开盘125.01元，最高125.5元，最低121.35元，成交额达26.22亿元，换手率为6.72%。凯莱英于近日披露《关于公司股票交易异常波动的公告》。公告显示，公司股票于2026年3月31日和4月1日连续两个交易日内收盘价格涨幅偏离值累计超过20%，构成股票交易异常波动。公司董事会确认无应披露而未披露事项，不存在违反信息披露公平性情形。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300032851.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","LU1328615791.USD","06821","002821","BK1191","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624590592","title":"凯莱英最新公告：股票交易异常波动","url":"https://stock-news.laohu8.com/highlight/detail?id=2624590592","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624590592?lang=zh_cn&edition=full","pubTime":"2026-04-01 19:09","pubTimestamp":1775041792,"startTime":"0","endTime":"0","summary":"凯莱英公告称，公司股票在2026年3月31日、4月1日连续两个交易日内收盘价格涨幅偏离值累计超过20%，属于股票交易异常波动。此外，公司于3月30日审议通过了2025年年度报告及利润分配预案等相关议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100036618.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","06821","BK0239","002821","LU1328615791.USD","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624599484","title":"4月1日凯莱英（002821）龙虎榜数据：机构净买入5723.67万元，北向资金净买入1576.32万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2624599484","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624599484?lang=zh_cn&edition=full","pubTime":"2026-04-01 17:19","pubTimestamp":1775035183,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年4月1日公布的交易公开信息显示，凯莱英因日涨幅偏离值达到7%的前5只证券，连续三个交易日内，涨幅偏离值累计达到20%的证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年4月1日收盘，凯莱英报收于121.85元，上涨10.0%，换手率6.03%，成交量19.13万手，成交额22.37亿元。从龙虎榜公布的当日买卖数据来看，机构合计净买入5723.67万元，北向资金合计净买入1576.32万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100031581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","06821","BK1191","BK0132","LU1328615791.USD","002821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624596505","title":"凯莱英：公司是一家全球行业领先的CDMO一站式综合解决方案提供商","url":"https://stock-news.laohu8.com/highlight/detail?id=2624596505","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624596505?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:48","pubTimestamp":1775033292,"startTime":"0","endTime":"0","summary":"证券之星消息，凯莱英04月01日在投资者关系平台上答复投资者关心的问题。公司是一家全球行业领先的CDMO一站式综合解决方案提供商，致力于全球制药工艺的技术创新和商业化应用，核心业务聚焦在法规监管要求严、供货量级大的产品阶段。相关情况请详见公司已披露的2025年度报告，感谢您的关注！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100030079.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","LU1328615791.USD","BK0239","002821","06821","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624596345","title":"凯莱英：公司近年推行的降本增效措施成果显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2624596345","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624596345?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:45","pubTimestamp":1775033137,"startTime":"0","endTime":"0","summary":"证券之星消息，凯莱英(002821)04月01日在投资者关系平台上答复投资者关心的问题。投资者提问：2025年年报披露，公司本期营业收入变化率与销售费用和管理费用变化率相差24%，请问公司财务报表是否有问题？财务数据是否真实反映？凯莱英回复：尊敬的投资者，您好！公司近年推行的降本增效措施成果显著，年度报告真实反应了公司生产经营成果。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100030020.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002821","BK0132","LU1328615791.USD","06821","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623379186","title":"CXO概念股强势 凯莱英(06821)涨13.85% 机构认为CXO基本面拐点已经出现","url":"https://stock-news.laohu8.com/highlight/detail?id=2623379186","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623379186?lang=zh_cn&edition=full","pubTime":"2026-03-31 10:23","pubTimestamp":1774923794,"startTime":"0","endTime":"0","summary":"金吾财讯 | CXO概念股强势，凯莱英(06821)涨13.85%，昭衍新药(06127)涨7.34%，药明生物(02269)涨5.99%，康龙化成(03759)涨4.54%，药明康德(02359)涨4.12%，泰格医药(03347)涨2.89%，金斯瑞生物科技(01548)涨1.09%。浙商医药团队分析指出，在CXO产业持续出清，股价相对低位背景下，看好本土头部CDMO企业和受益国内需求复苏CRO企业底部投资机会。从财务、需求和供给数据分析，该机构认为CXO基本面拐点已经出现，并有望持续复苏。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/YjA5ZTU5M2U3ZjIyNGI4Mzk2MWM1NGUyNWZkZjFmMjE3MzEwNTIzMzcxNTY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjA5ZTU5M2U3ZjIyNGI4Mzk2MWM1NGUyNWZkZjFmMjE3MzEwNTIzMzcxNTY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977810","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348825331.USD","LU0823426308.USD","LU3063872942.SGD","03347","LU0823426480.USD","HK0000306685.HKD","LU0516422366.SGD","LU0359201612.USD","LU1880383366.USD","IE00B0JY6N72.USD","LU0588546209.SGD","LU0856984785.SGD","06127","LU0456827905.SGD","LU0979878070.USD","LU0456846285.SGD","BK1576","LU1794554557.SGD","LU1328615791.USD","LU0516423091.SGD","LU0052750758.USD","LU0516423174.USD","LU0307460666.USD","LU0051755006.USD","LU0348735423.USD","LU0417516738.SGD","HK0000306701.USD","BK1521","LU0516422440.USD","LU2045819591.USD","CXO","03759","LU0320764599.SGD","LU0326950275.SGD","LU0572944931.SGD","LU0043850808.USD","02359","LU1688375341.USD","BK1589","LU0181495838.USD","LU1242518857.USD","01548","LU0327786744.USD","LU1046422090.SGD","002821","LU0819121731.USD","LU0039217434.USD","LU0140636845.USD","02269","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623341589","title":"凯莱英(06821)发布年度业绩 归母净利润约11.33亿元，同比增加19.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623341589","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623341589?lang=zh_cn&edition=full","pubTime":"2026-03-30 22:51","pubTimestamp":1774882314,"startTime":"0","endTime":"0","summary":"智通财经APP讯，凯莱英(06821)发布截至2025年12月31日止年度业绩，该集团取得收益约66.70亿元(人民币，下同)，同比增长14.91%;归属于上市公司股东的净利润约11.33亿元，同比增加19.35%;每股基本盈利3.16元。拟派付每10股普通股人民币13.00元(含税)。公告称，公司秉承“做深”大客户，逐步延伸服务链。报告期内，来自大型制药公司收入人民币29.16亿元，同比增长8.36%;公司坚持“做广”中小客户，储备潜力项目。来自中小制药公司收入人民币37.55亿元，同比增长20.57%，收入来源呈现更为多元的趋势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422253.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002821","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623311483","title":"Schroders PLC增持凯莱英(06821)8.85万股 每股作价约79.03港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2623311483","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623311483?lang=zh_cn&edition=full","pubTime":"2026-03-30 19:08","pubTimestamp":1774868890,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，3月26日，Schroders PLC增持凯莱英(06821)8.85万股，每股作价79.0296港元，总金额约为699.41万港元。增持后最新持股数目为562.14万股，持股比例为20.2%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421905.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","EWH","06821","LU1328615791.USD","002821","BK0132","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622074424","title":"凯莱英（002821）披露召开2026年第一次临时股东会等三会通知，3月25日股价上涨0.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622074424","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622074424?lang=zh_cn&edition=full","pubTime":"2026-03-25 22:10","pubTimestamp":1774447827,"startTime":"0","endTime":"0","summary":"截至2026年3月25日收盘，凯莱英报收于96.5元，较前一交易日上涨0.95%，最新总市值为348.24亿元。近日，凯莱英医药集团（天津）股份有限公司发布《关于召开2026年第一次临时股东会、2026年第一次A股类别股东会及2026年第一次H股类别股东会的通知》。会议将审议修订董事及高级管理人员薪酬管理制度、回购注销2025年A股限制性股票激励计划部分限制性股票、修订公司章程等议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032500043643.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06821","BK0132","BK1191","LU1328615791.USD","BK0239","002821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619461785","title":"凯莱英（002821）披露董事会会议日期公告，3月16日股价下跌0.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619461785","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619461785?lang=zh_cn&edition=full","pubTime":"2026-03-16 22:29","pubTimestamp":1773671358,"startTime":"0","endTime":"0","summary":"截至2026年3月16日收盘，凯莱英报收于99.08元，较前一交易日下跌0.23%，最新总市值为357.55亿元。该股当日开盘98.94元，最高100.74元，最低97.08元，成交额达2.66亿元，换手率为0.85%。近日，凯莱英医药集团（天津）股份有限公司发布H股公告，宣布将于2026年3月30日举行董事会会议，考虑及批准公司及其附属公司截至2025年12月31日止年度业绩的发布，并考虑建议派发末期股息（如有）。公告同时列出了董事会成员名单。本公告由董事长Hao Hong博士代表董事会签署。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600036892.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1328615791.USD","002821","BK0132","BK1191","06821","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619719796","title":"凯莱英(06821)购回及注销部分根据2025年A股计划授予的限制性A股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2619719796","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619719796?lang=zh_cn&edition=full","pubTime":"2026-03-13 20:57","pubTimestamp":1773406667,"startTime":"0","endTime":"0","summary":"智通财经APP讯，凯莱英(06821)发布公告，于2026年3月13日，本公司董事会审议并通过了“关于购回及注销 2025年A股计划项下部分限制性股份的议案”，据此将购回及注销共计6.1万股由 (i)四名已辞职激励对象根据2025年A股计划首次授予，及(ii)一名已辞职激励对象根据2025年A股计划预留授予项下所持有的已授出但尚未解禁的限制性A股股份(购回及注销事项)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413859.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","399300","BK0239","159982","06821","BK0132","002821","LU1328615791.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619219669","title":"凯莱英：拟使用45.00亿闲置自有资金购买理财产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2619219669","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619219669?lang=zh_cn&edition=full","pubTime":"2026-03-13 18:40","pubTimestamp":1773398408,"startTime":"0","endTime":"0","summary":"南财智讯3月13日电，凯莱英公告，公司及合并报表范围内子公司拟使用额度不超过45.00亿元人民币（或等额外币，含本数）的闲置自有资金购买安全性高、流动性好的短期金融机构理财产品，使用期限自2026年3月13日第五届董事会第七次会议审议通过之日起不超过12个月，在上述额度和期限内，资金可循环使用。该事项已经公司董事会审议通过，无需提交股东大会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603133671676352.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","002821","BK0132","LU1328615791.USD","06821","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616641326","title":"凯莱英（002821）披露证券变动月报表，3月3日股价下跌2.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616641326","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616641326?lang=zh_cn&edition=full","pubTime":"2026-03-03 22:18","pubTimestamp":1772547505,"startTime":"0","endTime":"0","summary":"截至2026年3月3日收盘，凯莱英报收于92.5元，较前一交易日下跌2.05%，最新总市值为333.81亿元。近日，凯莱英医药集团（天津）股份有限公司提交截至2026年2月28日的证券变动月报表。公司H股和A股的法定/注册股本均无变动，H股总数为27,834,510股，A股总数为333,040,460股，其中A股包含1,151,300股库存股。已发行股份总数保持不变，H股无库存股。公司确认H股公众持股量符合联交所规定的5%最低门槛。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300044360.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002821","BK0239","161027","BK0132","LU1328615791.USD","06821","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131840699","title":"花旗集团增持凯莱英H股，持股比例从9.34%升至11.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=1131840699","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131840699?lang=zh_cn&edition=full","pubTime":"2026-02-25 19:32","pubTimestamp":1772019171,"startTime":"0","endTime":"0","summary":"根据香港交易所披露的最新权益资料，花旗集团于2月19日增持了凯莱英的H股股份，其持有的好仓权益比例由9.34%增加至11.67%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821","BK0239","002821","BK0132","LU1328615791.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611715405","title":"小摩增持凯莱英(06821)9400股 每股作价约87.56港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611715405","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611715405?lang=zh_cn&edition=full","pubTime":"2026-02-13 20:43","pubTimestamp":1770986605,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，2月10日，小摩增持凯莱英(06821)9400股，每股作价87.5591港元，总金额约为82.31万港元。增持后最新持股数目约为167.41万股，最新持股比例为6.01%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1405425.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4533","LU0211327993.USD","LU0323591593.USD","IE00BJTD4V19.USD","LU1548497426.USD","LU2054465674.USD","002821","LU0170899867.USD","LU0251132253.USD","BK4566","LU1244550577.SGD","LU0211326839.USD","LU2237443465.HKD","LU1280957306.USD","LU0256863811.USD","LU1720051017.SGD","LU1974910355.USD","LU1551013425.SGD","LU0211326755.USD","LU0149725797.USD","LU2746668461.USD","LU0971096721.USD","LU0203347892.USD","LU0211331839.USD","LU2242649171.HKD","LU2381873111.SGD","LU0238689110.USD","LU2430703251.USD","LU0215105999.USD","LU0203345920.USD","LU1629891620.HKD","IE00BJLML261.HKD","LU1328615791.USD","LU0820561909.HKD","LU1670627923.USD","IE00BLSP4239.USD","LU2430703095.HKD","IE00BYXW3230.USD","BK0132","LU0208291251.USD","LU0882574139.USD","IE00BBT3K403.USD","LU2417539215.USD","LU2552382132.HKD","06821","LU0943347566.SGD","LU0267386448.USD","LU0976567544.SGD","IE00B3S45H60.SGD","LU1894683264.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776339741706,"stockEarnings":[{"period":"1week","weight":-0.0073},{"period":"1month","weight":0.1894},{"period":"3month","weight":0.1066},{"period":"6month","weight":0.1442},{"period":"1year","weight":0.8683},{"period":"ytd","weight":0.2682}],"compareEarnings":[{"period":"1week","weight":0.0081},{"period":"1month","weight":-0.0141},{"period":"3month","weight":-0.0208},{"period":"6month","weight":0.0488},{"period":"1year","weight":0.2324},{"period":"ytd","weight":0.0147}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"凯莱英医药集团(天津)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"0人","perCapita":"--","listingDate":"2016-11-18","address":"天津市滨海新区经济技术开发区洞庭三街6号","registeredCapital":"36087万元","survey":" 凯莱英医药集团(天津)股份有限公司的主营业务是为国内外制药公司、生物技术公司提供药品全生命周期的一站式服务。公司的主要产品是小分子CDMO解决方案、新兴业务。凯莱英生物AsymBio偶联药物开发平台成功入围第12届WorldADCAwards“BestADCPlatformTechnology”奖项，印证了凯莱英生物在全球抗体偶联药物CDMO领域的卓越地位。","listedPrice":30.53},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"凯莱英(002821)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供凯莱英(002821)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"凯莱英,002821,凯莱英股票,凯莱英股票老虎,凯莱英股票老虎国际,凯莱英行情,凯莱英股票行情,凯莱英股价,凯莱英股市,凯莱英股票价格,凯莱英股票交易,凯莱英股票购买,凯莱英股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"凯莱英(002821)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供凯莱英(002821)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}